CTOs on the Move

Esperance Pharmaceuticals

www.esperancepharma.com

 
Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Esperance Pharmaceuticals raised $40M on 03/30/2016

Similar Companies

Registrat

Registrat, Inc. is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quark Pharmaceuticals

Quark Pharmaceuticals is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stago

Merck Sharp and Dohme

Today`s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.